Though therapeutic treatments are generally trialled, approved and introduced based on the assumption of correct usage, actual patient adherence has been shown across a range of situations to be less than 50%,
resulting in undertreated conditions, increased emergency admissions, and reduced public health outcomes. In the following editorial, David Griffin, Senior Consultant at 42 Technology answers the question: can technology alone tackle the issue of medicine adherence?
https://international-pharma.com/wp-content/uploads/2015/04/12.-Can-Technology-Alone-Tackle.pdf
Current Edition
Current Edition
Subsection - CDMO
Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.
Continue readingSubsection - Injectables
Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.
Continue readingSubsection - Neurodegenerative Diseases
Exploring emerging approaches to neurodegenerative disease research and treatment.
Continue readingSubsection - Nasal & Pulmonary
Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.
Continue reading
Can Technology Alone Tackle the Issue of Medicine Adherence?
